Alveltamig

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameAlveltamig
Drug Alias NameZG-006ZG006
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD3Anti-Delta-like protein 3
TargetsT cell surface glycoprotein CD3Delta-like protein 3
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsSmall Cell Lung Carcinoma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesSuzhou Zelgen Biopharmaceuticals Co LtdGensun Biopharma Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAbbvie IncSuzhou Zelgen Biopharmaceuticals Co LtdShanghai Zejing Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic NeoplasmsSmall Cell Lung Carcinoma +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A